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BACKGROUND: The eicosanoid signalling pathway promotes the progression of malignancies through the production of proliferative
prostaglandins (PGs). Cytosolic phospholipase A2a (cPLA2a) activity provides the substrate for cyclooxygenase-dependent
PG release, and we have previously found that cPLA2a expression correlated with EGFR/HER2 over-expression in a small number
of breast cancer cell lines.
METHODS: The importance of differential cPLA2a activity in clinical breast cancer was established by relating the expression of cPLA2a
in tissue samples from breast cancer patients, and two microarray-based gene expression datasets to different clinicopathological and
therapeutic parameters.
RESULTS: High cPLA2a mRNA expression correlated with clinical parameters of poor prognosis, which are characteristic of highly
invasive tumours of the HER2-positive and basal-like subtype, including low oestrogen receptor expression and high EGFR
expression. High cPLA2a expression decreased overall survival in patients with luminal cancers, and correlated with a reduced effect
of tamoxifen treatment. The cPLA2a expression was an independent predictive parameter of poor response to endocrine therapy in
the first 5 years of follow-up.
CONCLUSION: This study shows a role of cPLA2a in luminal breast cancer progression, in which the enzyme could represent a novel
therapeutic target and a predictive marker.
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Breast cancer is the most common malignancy diagnosed in
women and the leading cause of cancer-related death in women
worldwide, accounting for B500000 deaths per year and
representing 15% of all female cancer-related mortality (Hortobagyi
et al, 2005). Early detection and improved treatment account for the
decline in mortality rates that has been observed in the past two
decades (Jemal et al, 2007). Molecular characterisation and profiling
has improved our understanding of the heterogeneity of breast
cancer, and is now an important clinical tool to predict the course of
the disease and identify the most appropriate treatment regimen for
each patient (Perou et al, 2000; Sorlie et al, 2001; Hu et al, 2006).
Accordingly, oestrogen receptor (ER)-positive patients are treated
with adjuvant endocrine therapy (such as tamoxifen or fulvestrant;
Jordan, 2007), and HER2-positive patients can benefit from targeted
agents, such as trastuzumab or lapatinib (Rabindran, 2005).
However, the vast majority of patients treated with adjuvant systemic
therapy do not respond to the treatment or develop acquired
resistance. Furthermore, patients with ER-negative, progesterone
receptor (PR)-negative and HER2-negative tumours (triple-negative,
or basal-like cancers) lack an established therapeutic target and can
only be treated with conventional chemotherapy (Linn and Van ‘t
Veer, 2009). It is, therefore, crucial to improve the translational effort
in order to identify molecular markers that could aid in the
prediction of tumour progression, prognosis and therapeutic regi-
men.
The group IVA cytosolic phospholipase A2 (cPLA2a)i sa n
enzyme that catalyses the hydrolysis of the sn-2 linkage in
membrane glycerol–phospholipids to release arachidonic acid
(AA), which is then converted to biologically active eicosanoid
lipid mediators, including prostaglandin E2 (PGE2), produced by
cyclooxygenase (COX)-2 (Leslie, 1997). The PGE2 has important
regulatory roles in diverse cellular responses, including cell growth
and differentiation; accordingly, the AA-based eicosanoid signal-
ling pathway has been implicated in the development and
progression of cancer in different human tissues, including the
breast (Nakanishi and Rosenberg, 2006; Thomas et al, 2008).
Clinical, epidemiological and molecular evidence has linked COX-2
expression/activation and PGE2 production to breast cancer
progression (reviewed in Howe, 2007). We have previously
reported that cPLA2a can be rapidly activated by physiological
concentrations of 17b-estradiol (E2) and is involved in the
proliferative effects of E2 in breast cancer cell (Thomas et al,
2006, 2008; Caiazza et al, 2010). Specifically, the E2-induced
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HER2 heterodimers signalling through ERK1/2 mitogen-activated
protein kinase (Caiazza et al, 2010), resulting in the activation of
proliferative signals in both ER-positive and ER-negative breast
cancer cells. Pre-clinical data support a role for EGFR/HER2
signalling in promoting E2-independent tumour growth and in the
development of resistance to endocrine therapy (Knowlden et al,
2003). In agreement with these data, clinical evidence shows that
over-expression of both EGFR and HER2, which is found in 50%
and 30% of breast cancers, respectively, correlates with a decreased
sensitivity to endocrine therapy and with poor patient prognosis
(Pietras, 2003). Furthermore, over-expression of HER2 receptors
and related signalling intermediates is a molecular determinant of
selective loss of ER expression, progression to ER-negative
invasive phenotype and development of resistance to selective
ER modulator-based therapy (Lopez-Tarruella and Schiff, 2007).
Consequently, in the past 20 years, HER2 has become an important
prognostic marker and therapeutic target in breast cancer. Taking
into account the involvement of EGFR/HER2 receptors in the
E2-induced activation of cPLA2a in breast cancer cell lines, it was
hypothesised that cPLA2a activity and expression could be
correlated with HER2-overexpressing tumours, a suggestion that
is also supported by previous studies showing a correlation
between expression of intermediates in the eicosanoid signalling
pathway, particularly COX-2, and HER2 over-expression in breast
cancer (Vadlamudi et al, 1999; Ristimaki et al, 2002; Subbaramaiah
et al, 2002; Wulfing et al, 2003). We previously reported a novel
correlation between cPLA2a and HER2 over-expression in a small
number of cell lines (Caiazza et al, 2010). This study investigates
the relationship between cPLA2a and EGFR/HER2 in vivo,
addressing the clinical implications of differential cPLA2a expres-
sion in breast cancer.
PATIENTS AND METHODS
Patient samples and quantitative real-time PCR
(qRT–PCR)
Ethical approval and patient consent was obtained for access to
primary tumour samples from 18 breast cancer patients who
underwent surgery at Beaumont Hospital (Dublin, Ireland)
between 2008 and 2009. In all, 15 patients were ER positive and
3 were ER negative as determined by standard histopathological
evaluation. The patients had not been treated with adjuvant
endocrine therapy; however, the majority had received selective
oestrogen receptor modulator therapy with tamoxifen. The
complete clinicopathological characteristics are summarised in
Supplementary Table S1.
RNA extraction and qRT–PCR were performed as previously
described (Caiazza et al, 2010). Expression levels of HER2
mRNA were normalised to a standard housekeeping gene (18S
rRNA) and calibrated to the MCF-7 cell line chosen to represent
1  expression of HER2 gene (Barberis et al, 2008) All samples
above a threshold of HER2 mRNA expression relative to the
calibrator were assigned to the HER2-positive group. This method
was previously validated by comparing HER2 mRNA levels in
55 formalin-fixed, paraffin-embedded samples, in which HER2
status was evaluated by IHC and fluorescence in situ hybridisation
(Barberis et al, 2008).
Gene expression microarrays
The expression of PLA2G4A (probe 210145_at), EGFR (probe
210984_x_at) and ERBB2 (probe 210930_s_at) was examined in
two previously published microarray data sets of breast cancer cell
lines (Kao et al, 2009) and primary tumour samples (van de
Vijver et al, 2002), which had been profiled with an Affymetrix
microarray assay (Affymetrix, Santa Clara, CA, USA). Data were
downloaded, respectively, from the PLOS website (http://dx.plos.
org/10.1371/journal.pone.0006146) and from the original publica-
tion on-line supporting information website (http://microarray-pubs.
stanford.edu/wound_NKI/explore.html). Comprehensive clinical data
of all 295 patients were also available from the same source.
Statistical analysis
Statistical analysis of the data was performed with paired Student’s
t-test for analysis between two groups. Fisher’s exact test was
performed on contingency tables to analyse the correlation between
two variables. Pearson’s coefficient was used to measure correlation
between linear variables. Survival curves were calculated according
to the Kaplan–Meier method and compared using the Cox–Mantel
log-rank test. Overall survival (OS) was calculated as the time
between the first date of treatment and the last date of follow-up or
the date of death. Relapse-free survival (RFS) was calculated as the
time between the first date of treatment and the last date of follow-
up or date of recurrence (loco-regional recurrence or distant
metastasis). Kaplan–Meier curves were calculated, as indicated,
over the entire follow-up time (17 years) or over a follow-up time of
10 years to focus on the effects on early development of acquired
endocrine resistance. All analyses were performed using prism
(Graphpad Software, La Jolla, CA, USA). Cox proportional hazard
models were computed using XLStat-Life for Microsoft Excel
(Kovach Computing Services, Anglesey Wales). The cPLA2a
expression was categorised as high or low using the upper median
as a cutoff point. Where indicated, the median was used as a cutoff
point to exclude any possible bias because of the low number of
patients. All other variables were either dichotomised or analysed as
continuous variables as indicated. The number of patients in each
group is reported in the figure legend. A heat-map image was
generated from microarray data using the Matrix2png web interface
(University of British Columbia, http://chibi.ubc.ca/matrix2png;
Pavlidis and Noble, 2003). All P-values are two-tailed, and P-values
of o0.05 were considered statistically significant.
RESULTS
Increased expression of cPLA2a mRNA correlates with
HER2 over-expression in breast cancer patients
The expression of cPLA2a was analysed by qRT–PCR in tumour
samples from a cohort of Irish breast cancer patients (complete
clinical data for the 18 patients are detailed in Supplementary
Table S1). Recently, the validity of IHC to test for HER2
amplification has been questioned in terms of standardisation,
reproducibility and accuracy (Gown, 2008), and different groups
have reported results supporting a better accuracy of qRT–PCR in
detecting HER2 amplification, avoiding false positives and false
negatives (Vinatzer et al, 2005; Kulka et al, 2006). Consequently,
we quantified HER2 expression in all 18 samples using qRT–PCR.
In all, 9 samples out of 18 (50%) scored as HER2 positive using the
described method, including some that were previously classified
as HER2 negative using standard pathological evaluation. Expres-
sion of cPLA2a mRNA was significantly (Po0.01) increased in
HER2-positive tissue samples (Figure 1).
Increased expression of cPLA2a mRNA correlates with
the basal-like and HER2-positive subtypes, and with
markers of poor prognosis in a panel of breast cancer
cell lines
With the aim of expanding our study to a larger sample size
population, we first analysed the expression of cPLA2a in a panel
of 30 breast cancer cell lines for which gene expression microarray
data were previously published (Kao et al, 2009). Increased
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sexpression of cPLA2a correlated with high expression of EGFR
and with low expression of ERa at the mRNA level (Figure 2A).
No significant correlation was found between cPLA2a and HER2
expression, but this was influenced by missing data for HER2
mRNA expression levels. High cPLA2a abundance clustered in cell
lines characterised by basal phenotype compared with luminal
phenotype, and cPLA2a expression also correlated with basal-like
and HER2-positive subtypes as opposed to luminal A and luminal
B subtypes (Figure 2B). High EGFR expression, low ERa, the basal
and HER2-positive subtypes are all molecular markers of poor
prognosis in breast cancer. High cPLA2a expression also correlated
with two different profile signatures that are predictive of poor
prognosis: the 70 gene (van ‘t Veer et al, 2002) and the wound
response (Chang et al, 2005) signatures (Figure 2B).
Increased expression of cPLA2a mRNA correlates with
clinical parameters of poor prognosis in a cohort of
breast cancer patients
Expression of cPLA2a was investigated in a second gene expression
microarray dataset comprising 295 breast cancer patients from The
Netherland Cancer Institute (van de Vijver et al, 2002). There was a
positive correlation between cPLA2a and EGFR mRNA expression
(Pearson R
2¼0.056, Po0.0001), but no correlation between
cPLA2a and HER2 expression (P¼0.7816). High cPLA2a mRNA
abundance correlated with ER-negative status as opposed to ER
positive (Po0.0001), and with basal phenotype compared with
luminal (Po0.0001; Figure 3A and B and Supplementary Table S2).
When compared with the TNM staging system, high cPLA2a
expression correlated with size of the primary tumour (T) of
42cm(Po0.05; Figure 3C) but not with lymph node involvement
(N) or with distant metastasis (M). Increased cPLA2a abundance
also correlated with histology grade 3 tumours compared with
grade 1 and 2 (Po0.05) and with the activated wound response
model (a gene signature predictive of poor prognosis (Chang et al,
2005)) (Po0.001). Correlation with the 70 gene profile signature
almost reached statistical significance (P¼0.0528; Figure 3D–F
and Supplementary table S2). In spite of the correlation between
high cPLA2a mRNA expression and different clinical parameters
characteristic of poor prognosis, cPLA2a itself was not associated
with poor prognosis in both univariate and multivariate analysis
(Figure 4 and Supplementary Table S3). Patients with high cPLA2a
expression had a reduced 7 years OS compared with patients
expressing low cPLA2a, but this was not statistically significant
(P¼0.1; Figure 4A). However, when the same analysis was
repeated separately on luminal and basal tumour patient data,
high cPLA2a expression was associated with reduced OS in patients
with luminal cancer (Po0.01; Figure 4B and C).
Increased expression of cPLA2a correlates with poor
response to endocrine therapy in breast cancer patients
Increased expression of EGFR/HER2 and decreased expression of
ERa are molecular markers associated with resistance to endocrine
therapy in breast cancer (Pietras, 2003). We investigated the
relationship between cPLA2a expression and the development
of endocrine resistance in The Netherland Cancer Institute cohort
Basal Luminal
Luminal-A
Luminal-B
HER2 positive
Basal
Normal
Positive
Negative
Log10 gene expression
–6
B
T
2
0
H
C
C
7
0
H
C
C
1
1
8
7
H
C
C
1
5
6
9
H
C
C
1
5
9
9
H
C
C
1
9
3
7
H
C
C
1
9
5
4
H
C
C
2
1
5
7
1
8
4
A
1
B
T
5
4
9
H
C
C
3
8
H
S
5
7
8
T
H
C
F
1
0
A
H
D
A
2
3
1
H
D
A
4
3
6
S
U
H
1
0
2
S
U
H
1
4
9
B
T
4
7
4
E
F
H
1
9
H
C
C
1
0
0
7
H
C
C
1
5
0
0
H
C
C
2
6
8
8
H
D
A
1
3
4
H
D
A
1
7
5
S
U
H
5
2
S
U
H
1
9
0
T
4
7
D
U
A
C
C
8
9
3
Z
R
7
5
–
1
Z
R
7
5
–
3
0
PLA2G4A
EGFR
ESR1
ERBB2
6
Subtype
70 gene
Wound
ER
Figure 2 Correlation between cPLA2a mRNA expression and clinicopathological characteristics in a panel of 30 breast cancer cell lines. (A) Log2
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Figure 1 Expression of cPLA2a mRNA according to HER2 expression in
breast cancer tissue samples. Samples from 18 breast cancer patients were
separated into HER2-positive and HER2-negative groups according to
qRT–PCR quantification and threshold of HER2 expression, as indicated in
Materials and methods. Expression of cPLA2a mRNA, measured by qRT–
PCR, was compared amongst the two groups. **Po0.01 measured by
Student’s t-test.
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sof 295 breast cancer patients (see Supplementary Table S4 for
subset sizes). Although patients who expressed cPLA2a most
highly, had a reduced RFS when treated with endocrine therapy
compared with patients who received no adjuvant hormonal
treatment, according to Kaplan–Meier univariate survival analysis,
these data did not reach statistical significance (P¼0.56 and
ER status
–0.10
–0.05
0.00
0.05
0.10
0.15 Negative (n=69)
Positive (n=226)
P<0.0001
Fisher: P<0.01
L
o
g
1
0
 
c
P
L
A
2
 
 
e
x
p
r
e
s
s
i
o
n
Histologic grade
–0.09
–0.07
–0.05
–0.03
–0.01
0.01 1 (n=75)
2 (n=101)
3 (n=119)
P<0.05
L
o
g
1
0
 
c
P
L
A
2
 
 
e
x
p
r
e
s
s
i
o
n
Phenotype
–0.15
–0.10
–0.05
0.00
0.05
0.10 Basal (n=95)
Luminal (n=200)
P<0.0001
Fisher: P<0.001
L
o
g
1
0
 
c
P
L
A
2
 
 
e
x
p
r
e
s
s
i
o
n
Wound response model
–0.10
–0.05
0.00
0.05 Activated (n=126)
Quiescent (n=169)
P<0.001
L
o
g
1
0
 
c
P
L
A
2
 
 
e
x
p
r
e
s
s
i
o
n
Size of primary tumor (T staging)
–0.10
–0.08
–0.06
–0.04
–0.02
0.00
0.02 <2cm (n=155)
>2cm (n=140)
P<0.05
L
o
g
1
0
 
c
P
L
A
2
 
 
e
x
p
r
e
s
s
i
o
n
70 gene prognosis signature
–0.10
–0.08
–0.06
–0.04
–0.02
0.00
0.02 Good (n=115)
Poor (n=180)
P=0.0528
L
o
g
1
0
 
c
P
L
A
2
 
 
e
x
p
r
e
s
s
i
o
n
Figure 3 Correlation between cPLA2a mRNA expression and clinicopathological characteristics in 295 breast cancer patients. Log10 expression of
cPLA2a compared with (A) ER status, (B) basal-luminal phenotype, (C) size of primary tumour, (D) histology grade, (E) the wound response signature and
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Figure 4 Prognostic value of cPLA2a expression on the overall survival of 295 breast cancer patients. Kaplan–Meier analysis of the probability of overall
survival among (A) all 295 breast cancer patients (high n¼45 vs low n¼112), or patients with (B) basal (high n¼23 vs low n¼31) and (C) luminal
cancers (high n¼13 vs low n¼62), according to cPLA2a expression. Survival curves were compared with the Cox-Mantel log-rank test, and the
corresponding P-value is indicated.
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sP¼0.09, respectively; Figure 5A). However, the increased RFS
measured in patients treated with adjuvant hormonal therapy
compared with patients only treated with local therapy (log-rank
test, Po0.05) was completely lost in the subset of patients
expressing high levels of cPLA2a (P¼0.33), with the most
pronounced difference between the cPLA2a-positive patients and
the whole cohort observed within the first 5 years after diagnosis
(Figure 5B). For the whole cohort of patients, endocrine therapy
increased the mean time before first metastasis by 1 year compared
with receiving local therapy only (8.52±0.45 and 7.54±0.29 years,
respectively), and increased the number of patients free of distant
metastasis 5 years after diagnosis by 18% (76.3% with hormonal
therapy vs 58.6% with no hormonal therapy). These effects were
lost in high cPLA2a-expressing patients, for both the mean time
before first metastasis (7.11±0.72 years with hormonal therapy vs
7.96±0.42 years without hormonal therapy) and the percentage of
patients free of distant metastasis at 5 years after diagnosis (64.7%
with hormonal therapy vs 64.9% without hormonal therapy).
A Cox proportional multivariate analysis performed on this data
set (Table 1) showed that low cPLA2a mRNA expression and
adjuvant hormonal therapy were independent prognostic factors,
and were predictive of increased RFS in the first 5 years of patient
follow-up (odds ratio: 0.244, 95% CI: 0.069–0.862, Po0.05). This
analysis also included ER and HER2 expression as continuous
variables.
DISCUSSION
The role of eicosanoid signalling in carcinogenesis has been the
subject of intense investigation over the past 20 years, particularly
in the context of COX-2 over-expression. The dysregulation of
cPLA2a, through alterations in its functional activity or in
expression levels, is also a common feature of many types of
human cancer including mammary adenocarcinoma, leading to
high levels of proliferative eicosanoids (Nakanishi and Rosenberg,
2006; Thomas et al, 2008). Antagonism of cPLA2a would limit free
intracellular arachidonic acid availability; this in turn would have a
dual effect on tumour cells by reducing proliferative PGE2
production and also block the supply of arachidonic acid to
alternate pathways, such as those mediated by COX-1 and
lipoxygenase. This alternate metabolism of arachidonic acid
represents a serious negative side effect that was reported with
the clinical use of COX-2-specific inhibitors, which may be over
come through specific cPLA2a antagonism (Laye and Gill, 2003).
We previously demonstrated that selective pharmacological
inhibition of cPLA2a leads to the growth inhibition of breast
cancer cells in vitro (Caiazza et al, 2010). It is, therefore, crucial to
determine whether cPLA2a has any value as a putative therapeutic
target in vivo, and also to investigate which specific subset of
breast cancer patients may benefit the most from such interven-
tion. We previously found through in vitro studies that there was a
correlation between high cPLA2a expression and HER2 over-
expression at both mRNA and protein level in a small panel of
breast cancer cell lines (Caiazza et al, 2010). This expression
correlation may be explained by a bi-directional cross-talk
between the two proteins; where by HER2 can regulate the
expression of cPLA2a which in turn functions by modulating the
transcription of HER2 through the production of PGE2 (Benoit
et al, 2004; Caiazza et al, 2010). A similar synergy was also reported
between HER2 and COX-2 expression (Benoit et al, 2004; Wang
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Figure 5 Role of cPLA2a in the early development of endocrine resistance in 295 breast cancer patients. Kaplan–Meier analysis of the probability that
patients would remain free of distant metastases (A) among patients treated only with radiotherapy/chemotherapy and patients treated with adjuvant
tamoxifen therapy, according to cPLA2a expression (high, n¼31 vs low, n¼224 for radio/chemotherapy and high, n¼5 vs low, n¼35 for adjuvant
therapy), total follow-up time of 17 years; (B) among all patients or patients with high cPLA2a expression, according to the presence or absence of adjuvant
endocrine therapy (non-endocrine, n¼203 vs endocrine, n¼38 for all patients; non-endocrine, n¼94 vs endocrine, n¼17 for cPLA2a positive patients),
follow-up time of 10 years; (A and B) Survival curves were compared using the Cox–Mantel log-rank test. The corresponding w
2 values and P-values are
indicated. The threshold for cPLA2a dichotomisation in (B) was lowered to the median in order to include more patients; the statistical significance was
retained as compared with the analysis with the median cutoff point (not shown), suggesting the absence of bias because of the low number of patients.
Table 1 Multivariable proportional-hazard (cox) analysis of the risk of
distant metastasis as a first event within 5 years of diagnosis
Variable
Hazard
ratio (95% CI
a) P-value
Low cPLA2a (vs high) 0.244 (0.069–0.862) 0.028
Hormonal therapy (vs no hormonal therapy) 0.384 (0.172–0.855) 0.019
Abbreviations: CI¼confidence interval, cPLA2a¼cytosolic phospholipase A2a;
ER¼oestrogen receptor.
aCI (adjusted for ER and HER2 status). Total patients¼124
(hormonal¼20, no hormonal¼104, PLA2a high¼4, PLA2a low¼120).
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set al, 2004), and as a consequence COX-2 over-expression is
associated with HER2-driven tumourigenesis in vivo (Howe et al,
2005; Dillon et al, 2008). In this study, we report a correlation
between cPLA2a and high HER2 mRNA expression in a group of 18
breast cancer patients. This was subsequently confirmed by the
analysis of a gene expression microarray of 30 breast cancer cell
lines, in which high mRNA expression of cPLA2a correlated with
high EGFR expression and with the HER2-positive and basal-like
subtypes of breast cancer in cell lines showing basal phenotype.
The molecular classification of breast cancer, based on the seminal
work of Perou et al, 2000 (Sorlie et al, 2001), identified five main
subtypes of tumours with distinct patterns of gene expression and
different disease outcomes: luminal A and luminal B cancers
(mainly ER positive and sensitive to endocrine therapy), HER2
positive (ER negative or with low ER expression, HER2
over-expressing and resistant to endocrine therapy), basal-like
(ER negative, PR negative and HER2 negative, also called triple
negative) and normal-like. In our in silico analysis of gene
expression microarrays from both cell lines and patients, elevated
cPLA2a mRNA expression was associated with clinical parameters
for poor prognosis, which correlate with the HER2-positive and
basal-like subtypes of breast cancer. Low ER expression, high
EGFR expression, activation of poor prognosis profile signatures,
large tumour size and high histological grade all associated
significantly with high cPLA2a mRNA expression. So supporting
the hypothesis that cPLA2a could represent a specific therapeutic
target for a clinically challenging subset of breast cancer patients
with highly invasive, endocrine resistant tumours of the HER2-
positive or triple-negative subtype. In spite of the association
between cPLA2a expression and different clinicopathological
parameters characteristic of poor prognosis, cPLA2a was not
directly associated with poor prognosis, but only correlated with
reduced overall survival in patients with the luminal type of
cancer. This result suggested that cPLA2a could predict prognosis
specifically in luminal breast cancers, and hence be indicative of
the response to endocrine therapy. Over-expression of EGFR/
HER2 and downregulation of ER are molecular markers associated
with de novo and acquired resistance to endocrine therapy in both
pre-clinical models of breast cancer and in clinical studies
(Knowlden et al, 2003; Schiff et al, 2005). Several studies have
provided indirect evidence of a role for the eicosanoid signalling
pathway in the development of endocrine resistance, including the
PGE2-mediated, enhanced expression of HER2 (Benoit et al, 2004)
and expression of aromatase (Zhao et al, 1996). Direct evidence
also supports a role for COX-2 as an independent prognostic
marker for poor response to tamoxifen treatment in breast cancer
patients (Dillon et al, 2008). In this study, we analysed cPLA2a
expression with regards to hormonal treatment in a population of
295 breast cancer patients that were either treated with adjuvant
tamoxifen (alone or in combination with chemotherapy) or did not
receive any adjuvant endocrine treatment. High cPLA2a mRNA
was measured in only a small subset of the patients who received
endocrine therapy, and increased cPLA2a expression in this group
predicted poor response to endocrine therapy in the first 5 years of
follow-up in univariate analysis. The cPLA2a was also an
independent prognostic marker of poor response to endocrine
therapy in a multivariate analysis that also included hormonal
treatment, ER and HER2 expression to adjust for any bias
because of the association of cPLA2a expression with ER negativity
(which itself correlates with endocrine resistance). This analysis
only takes into account treatment with tamoxifen and does
not include other types of endocrine therapies, such as aromatase
inhibition.
In summary, the data presented in this work provide evidence of
a role for cPLA2a in breast cancer progression; cPLA2a expression
correlated with clinicopathological parameters of poor prognosis
and with highly aggressive tumours characterised by low ER
expression, high EGFR expression and basal phenotype. This work
also provides evidence to support a role for cPLA2a as a predictive
marker for poor prognosis, and suggest a role in the early onset of
resistance to tamoxifen therapy, in luminal cancers; this is in
common with what has been previously reported for COX-2
expression (Dillon et al, 2008). Targeting eicosanoid pathway
intermediates may prove a valuable strategy to overcome acquired
resistance to tamoxifen treatment of breast cancer, and it has been
suggested that specific antagonism of cPLA2a could be useful in
augmenting treatment (Thomas et al, 2008). In this study, we show
that patients with highly aggressive cancers of the HER2-positive
and basal-like subtypes, as well as patients with luminal tumours
who developed resistance to endocrine therapy, are most likely to
benefit from such a therapeutic strategy, due to their higher
cPLA2a expression levels.
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